Abstract INTRODUCTION Biological Alzheimer's disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient‐derived induced microglia‐like cell (iMG) profiles capture a functional dimension of AD progression beyond conventional plasma biomarke...
Min-Young Noh, Yeonsil Moon, Sung-Woo Kang et al.· Alzheimer's & Dementia· 0 citations
The emergence of blood-based biomarkers (BBMs) has transformed the diagnosis of Alzheimer’s disease (AD). 1,2 Plasma phosphorylated tau, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) have demonstrated remarkable accuracy in detecting amyloid pathology and predicting disease progression acr...
H. Kwon, Seong-Ho Koh· Journal of Clinical Neurolog...· 0 citations
In diabetic rats, oral administration of a curcumin-containing formulation was associated with fewer retinal vascular abnormalities and lower GFAP immunoreactivity, accompanied by parallel differences in inflammasome-related proteins.
Hyoseon Yu, J. Kang, Seo Hyun Kim et al.· Life· 0 citations
Plasma p-tau217 and p-tau181 are effective biomarkers for distinguishing biologically defined EOAD from EOFTD and adding NfL, GFAP, and APOE ε4 status further improves the discriminative accuracy for differentiating EOAD from EOFTD.
H. S. Kwon, So Young Moon, Mina Hwang et al.· Journal of Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
